Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in advanced biliary tract cancer (BTC)
Qin, S. Antonuzzo, L. Tougeron, D. Lee, C. K. Tan, B. J. Ikeda, M. Guthrie, V. McCoon, P. Lee, Y. S.
Qin, S.
Antonuzzo, L.
Tougeron, D.
Lee, C. K.
Tan, B. J.
Ikeda, M.
Guthrie, V.
McCoon, P.
Lee, Y. S.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Valle JW, Qin S, Antonuzzo L, Tougeron D, Lee CK, Tan BJ, et al. Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in advanced biliary tract cancer (BTC). Annals of Oncology. 2022 Nov;38(9):S1457-S. PubMed PMID: WOS:000897943700070.